Arizona State University

Arizona Board of Regents on Behalf of the University of Arizona

Martens, John A.

Brian S McKay

John Arthur Martens

Nicole R Congrove

Robert Snyder

Anna G Figueroa

John A Martens

The disclosure provides methods for treating or limiting development age-related macular degeneration, comprising (a) a GPR143 receptor agonist, including but not limited to L-DOPA, L-DOPA analogues, or a pharmaceutically acceptable salt thereof, and (b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof, and related compositions.

Compositions and methods for treating or limiting development of age-related macular degeneration

Methods and systems for screening therapeutic compositions for the treatment of age-related macular degeneration (AMD) or for the prevention of progression of AMD, wherein retinal pigment epithelium cells (RPE) are cultured and the level of hypoxia-induced exosome release from the RPE cells is subsequently measured. In the present invention, the level of hypoxia-induced exosome release can be correlated with AMD onset and severity.

Methods and systems for screening therapeutic compositions for treating age-related macular degeneration

The present invention provides methods for treating or limiting development of age-related macular degeneration, as well as methods for identifying compound suitable for such use.

Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment

Methods and compositions for treating and identifying compounds to treat age-related macular degeneration

Growing community of inventors

Tucson, AZ, United States of America

Brian S McKay